Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mesoblast ( (MESO) ) has provided an announcement.
On February 20, 2026, Mesoblast announced it will host a webcast to review operational highlights and financial results for the half year ended December 31, 2025. The event is scheduled for February 26–27, 2026, depending on time zone, and an archived version will later be available on the company’s investor website, providing shareholders and analysts with updated insight into its performance and development pipeline.
The update comes as Mesoblast advances its FDA-approved Ryoncil therapy and develops further indications for remestemcel-L and rexlemestrocel-L, supported by extensive global intellectual property protection extending to at least 2044. The webcast underscores the company’s efforts to communicate progress in scaling its industrialized manufacturing, expanding partnerships in Japan, Europe and China, and strengthening its position in the competitive cell therapy market.
The most recent analyst rating on (MESO) stock is a Hold with a $21.50 price target. To see the full list of analyst forecasts on Mesoblast stock, see the MESO Stock Forecast page.
Spark’s Take on MESO Stock
According to Spark, TipRanks’ AI Analyst, MESO is a Neutral.
Mesoblast’s overall stock score reflects a company with strong growth potential but significant financial challenges. The earnings call provided positive insights into market access and product launches, which are promising for future growth. However, financial performance and valuation concerns weigh down the score, with technical indicators suggesting caution due to overbought conditions.
To see Spark’s full report on MESO stock, click here.
More about Mesoblast
Mesoblast Limited is a biotechnology company specializing in allogeneic, off-the-shelf cellular medicines targeting severe and life-threatening inflammatory conditions. Its proprietary mesenchymal lineage cell therapy platforms, remestemcel-L and rexlemestrocel-L, underpin products such as Ryoncil, the first FDA-approved mesenchymal stromal cell therapy for pediatric steroid-refractory acute graft versus host disease, and are being advanced for additional inflammatory and cardiovascular indications across global markets.
Average Trading Volume: 222,175
Technical Sentiment Signal: Buy
Current Market Cap: $2.21B
See more data about MESO stock on TipRanks’ Stock Analysis page.